COMPOUNDS FOR THE TREATMENT OF JAK2-V617F-ASSOCIATED CMN

摘要

The present disclosure provides novel compounds for use in therapy of JAK2-V617F-associated chronic myeloproliferative neoplasia (CMN) and for use in therapy or prophylaxis of disorders or syndromes associated therewith, in particular splenomegaly and increased risk of thrombosis.